Allogene Therapeutics (ALLO) Return on Capital Employed (2018 - 2026)
Allogene Therapeutics (ALLO) reported Return on Capital Employed of 50.37% for Q1 2026, up 358.0% on a YoY basis from 11.0% in Q1 2025, and up 4.86% sequentially from 52.95% in Q4 2025.
Allogene Therapeutics (ALLO) Return on Capital Employed (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of Return on Capital Employed data on file, last reported at 50.37% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 358.0% year-over-year to 50.37%; the trailing twelve-month figure through Mar 2026 stood at 50.37% (up 358.0% YoY), and the FY2025 full-year result was 46.54%, up 223.0% from the prior year.
- Return on Capital Employed advanced to 50.37% in Q1 2026, from 52.95% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 23.22% in Q1 2022 to a low of 55.57% in Q2 2025.
- A 5-year average of 46.21% and a median of 50.71% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 2560 bps in 2023 and jumped 358 bps in 2026, its largest moves.
- Tracing ALLO's Return on Capital Employed over 5 years: stood at 41.72% in 2022, then decreased by 23 bps to 51.13% in 2023, then slipped by 0 bps to 51.22% in 2024, then slipped by 3 bps to 52.95% in 2025, then increased by 5 bps to 50.37% in 2026.
- Business Quant data shows ALLO's Return on Capital Employed at 50.37% in Q1 2026, 52.95% in Q4 2025, and 53.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | -50.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.37% |
| Dec 31, 2025 | -52.95% |
| Sep 30, 2025 | -53.71% |
| Jun 30, 2025 | -55.57% |
| Mar 31, 2025 | -53.96% |
| Dec 31, 2024 | -51.22% |
| Sep 30, 2024 | -50.87% |
| Jun 30, 2024 | -49.89% |
| Mar 31, 2024 | -51.08% |
| Dec 31, 2023 | -51.13% |
| Sep 30, 2023 | -48.04% |
| Jun 30, 2023 | -50.71% |
| Mar 31, 2023 | -48.81% |
| Dec 31, 2022 | -41.72% |
| Sep 30, 2022 | -27.07% |
| Jun 30, 2022 | -25.21% |
| Mar 31, 2022 | -23.22% |
| Dec 31, 2021 | -17.72% |
| Sep 30, 2021 | -23.94% |
| Jun 30, 2021 | -21.83% |